Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.

摘要: The introduction of highly potent direct-acting antivirals (DAAs) has revolutionized hepatitis C virus treatment. Nevertheless, viral eradication worldwide remains a challenge also in the era DAA treatment, because high associated costs, numbers undiagnosed patients, re-infection rates some risk groups and suboptimal drug efficacies with host factors as well advanced stages liver disease. A correct determination HCV genotype allows administration most appropriate antiviral regimen. Additionally, genetic sequencing improves our understanding resistance-associated variants, either naturally occurring before acquired by transmission at infection, or emerging after virological failure. Because treatment response rates, prevalence development resistance variants differ for each regimen genotype, this review summarizes opportunities per focuses on to guide clinical decision making. Although approval first pan-genotypic DAA-only is expected soon, will remain important when therapies fail, genotyping testing select new active combination be essential. Copyright © 2016 John Wiley & Sons, Ltd.